Verona Pharma Archives

COPD lung disease chronic obstructive pulmonary disease

News and Trends 20 Dec 2022

Verona Pharma drug meets COPD phase 3 trial endpoints

Verona Pharma plc has announced positive results of its phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The ENHANCE-1 trial successfully met its primary and key secondary endpoints demonstrating significant improvements in lung function, symptoms and quality of life measures. In addition, ensifentrine substantially reduced the […]

December 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 18 Oct 2022

Progress of COPD drug boosted by debt financing of up to $150M

Verona Pharma plc has today (October 17) announced that it has entered into a debt financing facility providing access of up to $150 million from Oxford Finance LLC. The non-dilutive capital provides further financial flexibility and support for commercialization activities for ensifentrine, the company’s product candidate, which recently reported positive phase 3 data in the […]

October 18, 2022 - 2 minutesmins - By Liza Laws

News and Trends 17 Oct 2022

More positive news announced for Verona’s COPD treatment

Clinical-stage biopharmaceutical company, Verona, has announced more positive news from its phase 3 ENHANCE-2 clinical trial of ensifentrine that treats chronic obstructive pulmonary disease (COPD). The company focuses on respiratory diseases, and made the announcement today (October 14) about the positive analyses demonstrating how ensifentrine reduced exacerbation rates across subgroups in the trial. Ensifentrine is […]

October 17, 2022 - 3 minutesmins - By Liza Laws

coronavirus COVID 19 Europe biotech lungs

News and Trends 19 Aug 2022

Nuance Pharma receives clearance to begin clinical trials with Ensifentrine in China

Nuance Pharma and its partner Verona Pharma plc have received clearance from the Center of Drug Evaluation for the investigational new drug (IND) application for ensifentrine. The application means both phase 1 and phase 2 studies looking at the drug for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in mainland China. In 2021, […]

August 19, 2022 - 2 minutesmins - By Liza Laws

More News! 5 Aug 2019

Phase II Promise for Inhaled Chronic Lung Disease Treatment

A first-in-class inhaled drug developed by the UK biotech Verona Pharma improved lung function in a phase II trial treating the lung condition chronic obstructive pulmonary disease. The 37 patients in the trial had chronic obstructive pulmonary disease (COPD), a common lung condition that involves a tightening of the lung airways and breathlessness. Verona Pharma […]

August 5, 2019 - 2 minutesmins - By Jonathan Smith

More News! 14 Jan 2019

Inhaled Lung Disease Treatment Encounters Mixed Results in Phase II Trial

An inhaled drug from British company Verona Pharma has failed to significantly improve lung function in patients with the lung disease chronic obstructive pulmonary disease, though it did produce some benefits. The 79 patients in the phase II trial suffered from chronic obstructive pulmonary disease, a condition where inflammation in the lungs restricts the airways […]

January 14, 2019 - 3 minutesmins - By Jonathan Smith

Interview 20 Jun 2018

“Have the guts to follow your instincts”: Top CEO Talks About His Time in Biotech

Some careers take on an international scope and span the breadth of big players in the pharmaceutical industry and small biotech startups. David Ebsworth, Chairman at Verona Pharma, can count his professional journey among these and gave us the inside scoop on the successes and challenges he faced, his perspective on European biotech, and advice to […]

June 20, 2018 - 9 minutesmins - By Alexander Burik

News and Trends 7 Sep 2017

Verona Achieves Successful Results for Phase IIa Trial of Deadly Lung Disease Drug

A study of Verona’s combination therapy for COPD observed a clinical improvement in lung function and faster onset-of-action. Verona filed for its US IPO and dosed the first patient in the trial in April, and it is now receiving initial results. This could explain a recent increase in their share price on the London Stock Exchange by […]

September 7, 2017 - 2 minutesmins - By Alex Dale

News and Trends 26 Jul 2017

Update: Potential Breakthrough Treatment for Deadly Lung Disease Starts Phase IIb

Update (26/07/2017): Verona Pharma has dosed the first patients in the PhaseIIb with RPL554 in patients with chronic obstructive pulmonary disease (COPD). Results are expected in the second half of 2018. Published on 27/06/2017 Verona Pharma has secured regulatory approval in five European countries to run a Phase IIb trial with its dual PDE3/4 inhibitor in […]

July 26, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 19 Apr 2017

UPDATE: Verona sets terms & dials back its IPO goal to a still-hefty €75M

UPDATE: Verona set the terms for its US IPO yesterday and knocked $10M (€9.3M) off its target, now shooting for $75M (€70M). The public shares are expected to hit the NASDAQ exchange next week. Original Publication 04/04/2017 British Verona Pharma has filed for an IPO on Nasdaq to raise up to €81M ($86M). The funds should be […]

April 19, 2017 - 3 minutesmins - By Melanie De Almeida

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us